Gentian News: Turbidimetric Cardiac Immunoassay

17. Dec 2019 | 2 min read

Gentian News: Turbidimetric Cardiac Immunoassay

Gentian has been granted a funding of 14M NOK distributed over 4 years for our project “Development of a rapid, affordable, high-throughput cardiac test” through the Research Council of Norway’s program “Innovation Project for the Industrial Sector

 

R&D objectives

The primary objective for the R&D activities in this project is to further develop and optimise Gentian’s highly sensitive and robust technology to develop a cardiac immunoassay for turbidimetric, fast, cost-effective and high volume clinical analysers, validated by solid clinical studies.

Torsten Knüttel, VP Research & Development, Gentian AS says: Within our cardiac biomarker project we aim to push the boundaries of particle-enhanced turbidimetric technology, and it is very positive to see that with this funding, the Research Council of Norway recognises Gentian’s expertise and leading position within this field.

Gentian has taken the approach of further innovating our existing technologies to allow measurement of low-concentration marker tests on existing high-throughput, low-cost clinical chemistry analysers, which are already the golden standard in all small and central laboratories.

 

Addressing the global challenge of heart failure and cardiac dysfunction

More than 26 million people worldwide are suffering from heart failure (HF) and cardiac dysfunction. The global burden of HF and cardiac dysfunction is increasing rapidly with the aging of the population, and it is one of the main global public health problems. A rapid, cost-effective test for heart failure will help address this issue. Hilja Ibert, CEO Gentian Diagnostics elaborates: “This project is an example on how Gentian focuses to improve diagnostic efficiency, by which we mean that we convert existing diagnostic tests to faster, less expensive and more efficient platforms. We are very pleased that Research Council of Norway see the potential in our innovations”.

 

The Research Council of Norway

The Research Council of Norway works to promote research and innovation of high quality and relevance and to generate knowledge in priority areas to enable Norway to deal with key challenges to society and the business sector.

 

You may also read


#FAQ: Avian antibodies – Immunoglobulin Y(IgY)

Jan 23, 2020

#FAQ: Avian antibodies – Immunoglobulin Y(IgY)

Avian antibodies in our commercial products since 2005 Gentian has applied avian antibodies with great..

CEO Interview at Arctic Securities

Jan 17, 2020

CEO Interview at Arctic Securities

Our CEO Dr. Hilja Ibert recently sat down with Pål Falck in Arctic Securities to have a look at Gentian's..

Diagnostic Efficiency by Gentian - Newsletter H1-2020

Jan 14, 2020

Diagnostic Efficiency by Gentian - Newsletter H1-2020

  Happy New Year 2020 We look forward to exhibiting at and visiting numerous trade shows and congresses..